Palatin Technologies

Palatin Technologies closed a reduced public offering raising approximately $1.1 million in gross proceeds through the sale of 7.3 million shares at $0.15 per share with accompanying warrants.

Palatin Technologies has presented preclinical data for PL9588, a novel melanocortin receptor agonist that demonstrates both IOP-lowering and neuroprotective effects for glaucoma treatment.

Updated Phase 3 analyses reveal PL9643 achieved complete symptom resolution across multiple endpoints in dry eye disease patients, a breakthrough not seen with any currently FDA-approved therapy.

Palatin Technologies' Phase 2b BREAKOUT study demonstrated that 71% of patients with Type 2 diabetic nephropathy achieved significant reductions in proteinuria and showed improved or stabilized kidney function after six months of treatment.

PL8177, a selective melanocortin-1 receptor agonist, achieved 33% clinical remission and 78% clinical response in ulcerative colitis patients compared to 0% and 33% for placebo, respectively, after eight weeks of treatment.

A fixed-dose combination of cagrilintide and semaglutide led to greater weight loss at 68 weeks compared to either drug alone or placebo in the REDEFINE 1 trial.

Palatin Technologies' Bremelanotide demonstrated positive results in a Phase IIb trial for Type 2 Diabetic Nephropathy, a leading cause of end-stage renal disease.

Palatin Technologies has completed enrollment in its Phase 2 study of oral PL8177 for ulcerative colitis, with topline data expected in Q1 2025.

Zealand Pharma reported positive Phase 1b results for petrelintide and dapiglutide, advancing both into Phase 2b trials for overweight and obese patients.

Palatin Technologies is focusing on obesity programs, including a Phase 2 study of BMT-801 with bremelanotide and tirzepatide, with topline results expected in Q1 2025.